How Topical Corticosteroids Calm Psoriatic Inflammation
Placeholder: steroids suppress immune signaling in psoriatic plaques.
- GR: Receptor (Placeholder short note)
- Days: Onset (Placeholder short note)
- 7: Potency classes (Placeholder short note)
- ↓ IL-17/23: Cytokines (Placeholder short note)
Glucocorticoid receptor signaling
Placeholder: steroid diffuses into keratinocytes and binds cytoplasmic receptor.
Vasoconstriction and cytokine suppression
Placeholder: reduces vasodilation, cytokine transcription, and cell trafficking.
Placeholder: potent steroids act fast but carry higher atrophy risk.
Vitamin D Analog Normalization of Keratinocyte Turnover
Placeholder: calcipotriol corrects abnormal keratinocyte proliferation.
- VDR: Receptor (Placeholder short note)
- Weeks: Onset (Placeholder short note)
- Low: Atrophy risk (Placeholder short note)
- ↓ Proliferation: Effect (Placeholder short note)
Vitamin D receptor activation
Placeholder: binds VDR, regulates keratinocyte differentiation genes.
Slower but atrophy-sparing action
Placeholder: takes longer to work but does not thin the skin.
Placeholder: good long-term option without steroid side effects.
Steroid Plus Calcipotriol — Complementary Mechanisms
Placeholder: combining agents targets inflammation and proliferation together.
- +: Efficacy gain (Placeholder short note)
- Yes: Steroid sparing (Placeholder short note)
- Fixed-dose: Formulation (Placeholder short note)
- Improved: Tolerability (Placeholder short note)
Complementary pathways
Placeholder: anti-inflammatory and antiproliferative actions combine.
Reduced cumulative steroid exposure
Placeholder: combination allows lower steroid potency or frequency.
Placeholder: combination often preferred as first-line regimen.
Epidermal and Dermal Thinning from Prolonged Steroid Use
Placeholder: chronic steroid exposure thins skin layers over time.
- ~3-4 wk: Risk onset (Placeholder short note)
- ↓ Synthesis: Collagen (Placeholder short note)
- Partial: Reversibility (Placeholder short note)
- Face/folds: High-risk sites (Placeholder short note)
Fibroblast suppression
Placeholder: steroids reduce collagen and fibroblast activity.
Clinical signs of atrophy
Placeholder: telangiectasia, striae, and fragile skin appear.
Placeholder: risk rises sharply with prolonged continuous use.
Cyclical Dosing to Balance Efficacy and Safety
Placeholder: time-capped and weekend-only regimens limit atrophy.
- 2-4 wk: Typical cap (Placeholder short note)
- Vit D: Maintenance (Placeholder short note)
- Weekend: Pulse dosing (Placeholder short note)
- Periodic: Monitoring (Placeholder short note)
Step-down and rotation strategies
Placeholder: taper steroid potency and rotate with vitamin D analog.
Long-term maintenance plan
Placeholder: calcipotriol maintenance minimizes relapse and atrophy.
Placeholder: duration limits protect skin integrity long-term.